• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Zydus, Gates Foundation To Develop Shigellosis-Typhoid Vaccine

    INDPHARMAPOST

    Valneva Reports Positive Phase 2 Chikungunya Vaccine Results

    GLOBENEWSWIRE

    PopVax Wins $2M BARDA Prize For Flu Vaccine Using Microarray Patch

    BUSINESSWIRE

    Nature Highlights Stratis® DNA Vaccine For Hantaviruses

    BUSINESSWIRE

    Vaxcyte Starts Phase 2 Study of VAX-31 in Infants

    GLOBENEWSWIRE

    Cyrus Biotech to Present Protein Engineering & IgG Protease Data

    BUSINESSWIRE

    Genprex Doses First SCLC Patient In Reqorsa+Tecentriq Acclaim-3 Study

    PR NEWSWIRE

    Filing reveals how AbbVie`s $10B ImmunoGen offer won out

    FIERCE PHARMA

    ImmunoGen Presents Findings from Phase 1b/2 Study of Pivekimab Sunirine at ASH

    BUSINESSWIRE

    FDA Grants Priority Review of ImmunoGen’s Supplemental BLA for ELAHERE

    BUSINESSWIRE

    ImmunoGen Announces EMA Acceptance of MAA for Mirvetuximab Soravtansine

    BUSINESSWIRE

    ImmunoGen, Takeda Partner to Commercialize ELAHERE in Japan

    CONTRACT PHARMA

    ImmunoGen Announces Multi-Target Agreement with ImmunoBiochem

    BUSINESSWIRE

    ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine

    BUSINESSWIRE

    ELAHERE® Demonstrates 35% Reduction in the Risk of Death in Ovarian Cancer

    BUSINESSWIRE

    ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    ImmunoGen Announces Webcast of Presentation and Q&A at Jefferies Conference

    BUSINESSWIRE

    ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock

    BUSINESSWIRE

    ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial

    PRESS RELEASE

    ImmunoGen Announces Proposed Public Offering of Common Stock

    PRESS RELEASE

    ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    PRESS RELEASE

    ImmunoGen Announces Loan Financing for Up to $175M with Pharmakon Advisors

    BUSINESSWIRE

    Vertex pays ImmunoGen $15M to pair ADCs with CRISPR therapy

    FIERCE BIOTECH

    ImmunoGen Announces Agreement with Vertex for ImmunoGen`s ADC Technology

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.